Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
An important clinical trial announcement is good news for this healthcare stock. The post Bell Potter is tipping this exciting ASX healthcare stock to rise 80% appeared first on The Motley Fool ...
TLX591-Tx (lutetium-177 rosopatamab tetraxetan) is an investigational PSMA-targeted radio antibody-drug conjugate (rADC) for metastatic castration-resistant prostate cancer (mCRPC). The ProstACT ...
Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
The most frequent treatment-emergent AEs for belzutifan/lenvatinib were anemia (69.2%), hypertension (58.9%), and diarrhea (52.7%); the cabozantinib arm saw frequent diarrhea (70.1%), hypertension (56 ...
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
Abstracts presented at ASCO GU examined whether the radioligand therapy impacts or is affected by ARPIs or chemotherapy.
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
Overview of Ac‑225 PSMA therapy, what real patient cases can illustrate about the treatment pathway, and key steps for eligibility review and choosing a center.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results